MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MOLECULAR PARTNERS AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026
$3.66+0.10 (+2.81%)
Close on Oct 19, 2026
MOLECULAR PARTNERS AG revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Switzerland | CHF 0 | CHF 4.97M | CHF 7.04M | CHF 179.90M | CHF 0 | CHF 0 | – | – | -100.0% |
| United States | – | CHF 0 | CHF 0 | CHF 9.65M | CHF 9.33M | CHF 9.34M | CHF 20.38M | – | – |
From the segment and revenue-disaggregation notes of Molecular Partners's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.